WANY
TEVA icon

Wealthspire Advisors (New York)’s Teva Pharmaceuticals TEVA Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-210
Closed -$4.24K – 2710
2025
Q3 		$4.24K Buy
+210
New +$3.69K ﹤0.01% 2385
2023
Q3 		– Sell
-140,123
Closed -$1.06M – 618
2023
Q2 		$1.06M Sell
140,123
-10,000
-7% -$81.1K 0.02% 243
2023
Q1 		$1.33M Sell
150,123
-2,351
-2% -$23.2K 0.02% 202
2022
Q4 		$1.39M Sell
152,474
-67,649
-31% -$590K 0.03% 201
2022
Q3 		$1.78M Buy
220,123
+70,000
+47% +$619K 0.04% 157
2022
Q2 		$1.13M Sell
150,123
-170,000
-53% -$1.48M 0.02% 203
2022
Q1 		$3.01M Buy
320,123
+35,253
+12% +$294K 0.07% 99
2021
Q4 		$2.28M Buy
284,870
+142,519
+100% +$1.29M 0.05% 135
2021
Q3 		$1.39M Buy
+142,351
New +$1.33M 0.03% 208
2019
Q1 		– Sell
-16
Closed – – 706
2018
Q4 		$0 Buy
+16
New +$328 ﹤0.01% 916

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Wealthspire Advisors (New York)'s TEVA Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 210 shares — an estimated $4.24K sold.

Wealthspire Advisors (New York) first reported a position in TEVA in Q4 2018 and held it in 10 quarters. The position peaked at $3.01M in Q1 2022. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 210 Teva Pharmaceuticals shares in Q4 2025, an estimated $4.24K.
  • Wealthspire Advisors (New York) first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 10 quarters.
  • Wealthspire Advisors (New York)'s Teva Pharmaceuticals position peaked at $3.01M in Q1 2022.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.